Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Marinus Pharma (MRNS) Misses Q4 EPS by 4c, Revenues Beat
March 9, 2021 7:18 AM ESTMarinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.55), $0.04 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $1.55 million versus the consensus estimate of $1.04 million.
Although 2020 was extremely challenging for so many, we finished the year achieving several important milestones, which has provided momentum into 2021, said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. We remain on track to submit a new... More
